1. Market Research
  2. > Pharmaceutical Market Trends
  3. > MerLion Pharmaceuticals Pte Ltd - Product Pipeline Review - 2013

MerLion Pharmaceuticals Pte Ltd - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

MerLion Pharmaceuticals Pte Ltd - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “MerLion Pharmaceuticals Pte Ltd - Product Pipeline Review - 2013” provides data on the MerLion Pharmaceuticals Pte Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, MerLion Pharmaceuticals Pte Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from MerLion Pharmaceuticals Pte Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- MerLion Pharmaceuticals Pte Ltd - Brief MerLion Pharmaceuticals Pte Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MerLion Pharmaceuticals Pte Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MerLion Pharmaceuticals Pte Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MerLion Pharmaceuticals Pte Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate MerLion Pharmaceuticals Pte Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MerLion Pharmaceuticals Pte Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MerLion Pharmaceuticals Pte Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MerLion Pharmaceuticals Pte Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MerLion Pharmaceuticals Pte Ltd and identify potential opportunities in those areas.

Table Of Contents

MerLion Pharmaceuticals Pte Ltd - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
MerLion Pharmaceuticals Pte Ltd Snapshot 4
MerLion Pharmaceuticals Pte Ltd Overview 4
Key Information 4
Key Facts 4
MerLion Pharmaceuticals Pte Ltd - Research and Development Overview 5
Key Therapeutic Areas 5
MerLion Pharmaceuticals Pte Ltd - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
MerLion Pharmaceuticals Pte Ltd - Pipeline Products Glance 9
MerLion Pharmaceuticals Pte Ltd - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
MerLion Pharmaceuticals Pte Ltd Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
MerLion Pharmaceuticals Pte Ltd - Drug Profiles 12
finafloxacin 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
MerLion Pharmaceuticals Pte Ltd - Pipeline Analysis 14
MerLion Pharmaceuticals Pte Ltd - Pipeline Products by Therapeutic Class 14
MerLion Pharmaceuticals Pte Ltd - Pipeline Products by Route of Administration 15
MerLion Pharmaceuticals Pte Ltd - Pipeline Products By Mechanism of Action 16
MerLion Pharmaceuticals Pte Ltd - Recent Pipeline Updates 17
MerLion Pharmaceuticals Pte Ltd - Dormant Projects 18
MerLion Pharmaceuticals Pte Ltd - Locations And Subsidiaries 19
Head Office 19
Other Locations and Subsidiaries 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables


MerLion Pharmaceuticals Pte Ltd, Key Information 4
MerLion Pharmaceuticals Pte Ltd, Key Facts 4
MerLion Pharmaceuticals Pte Ltd - Pipeline by Indication, 2013 6
MerLion Pharmaceuticals Pte Ltd - Pipeline by Stage of Development, 2013 7
MerLion Pharmaceuticals Pte Ltd - Monotherapy Products in Pipeline, 2013 8
MerLion Pharmaceuticals Pte Ltd - Phase III, 2013 9
MerLion Pharmaceuticals Pte Ltd - Phase II, 2013 10
MerLion Pharmaceuticals Pte Ltd - Phase I, 2013 11
MerLion Pharmaceuticals Pte Ltd - Pipeline By Therapeutic Class, 2013 14
MerLion Pharmaceuticals Pte Ltd - Pipeline By Route of Administration, 2013 15
MerLion Pharmaceuticals Pte Ltd - Pipeline Products By Mechanism of Action, 2013 16
MerLion Pharmaceuticals Pte Ltd - Recent Pipeline Updates, 2013 17
MerLion Pharmaceuticals Pte Ltd - Dormant Developmental Projects,2013 18
MerLion Pharmaceuticals Pte Ltd, Other Locations 19

List of Figures


MerLion Pharmaceuticals Pte Ltd - Pipeline by Indication, 2013 6
MerLion Pharmaceuticals Pte Ltd - Pipeline by Stage of Development, 2013 7
MerLion Pharmaceuticals Pte Ltd - Monotherapy Products in Pipeline, 2013 8
MerLion Pharmaceuticals Pte Ltd - Pipeline By Therapeutic Class, 2013 14
MerLion Pharmaceuticals Pte Ltd - Pipeline By Route of Administration, 2013 15
MerLion Pharmaceuticals Pte Ltd - Pipeline Products By Mechanism of Action, 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.